Diltiazem
Diltiazem is a calcium channel blocker taken by mouth. The US label read, for Cardizem, lists one use: the management of chronic stable angina and angina due to coronary artery spasm. Cardizem CD and Cardizem LA are separate extended-release products with their own labels, which were not read.
Also called Cardizem · Diltiazem hydrochloride
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 3443; UNII OLH94387TE. The label names the substance as diltiazem hydrochloride, so UNII OLH94387TE is the UNII of the salt form and is a broad match. MeSH descriptor D004110 is Diltiazem. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the CARDIZEM (diltiazem hydrochloride) tablets, Bausch Health US LLC label, effective 2025-04-30 in openFDA (application NDA018602). Other diltiazem labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Not yet recruiting | Enrolling by invitation | Completed | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 1/2 | 0 | 0 | 1 | 0 | 1 |
| Phase 4 | 1 | 1 | 1 | 2 | 5 |
| All phases | 1 | 1 | 2 | 2 | 6 |
Conditions these trials study
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Atrial flutter
- Cardiomyopathy (heart muscle disease)
- Coronary artery disease
- Hypertension (high blood pressure)
- Hypertrophic cardiomyopathy
- Microvascular and vasospastic angina
Sponsors with the most trials
- Asker & Baerum Hospital
- Charite University, Berlin, Germany
- Mahidol University
- Mercy Health Muskegon
- Second Affiliated Hospital, Zhejiang University, School of Medicine
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
OLH94387TE
Claims and evidence
Context People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with chronic stable angina
- Patients with angina due to coronary artery spasm
- Excluded
- None stated
The US label of CARDIZEM (diltiazem hydrochloride), in the Bausch Health US LLC version dated 2025-04-30 in openFDA, lists the medicine for the management of chronic stable angina and angina due to coronary artery spasm.
Applies to Recipient not specified People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-04-30
- Source state
- Current
- Version fingerprint
31d00490399711edd34a07a6130c2ebbb66e5d41bbddddf7b5da4f66b78e7d14- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250430.
- Retrieved
- Source effective date
- 2025-04-30
- Source state
- Current
- Version fingerprint
31d00490399711edd34a07a6130c2ebbb66e5d41bbddddf7b5da4f66b78e7d14- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
CARDIZEM
No label from the application holder was found in the openFDA label dataset for application NDA018602. This page does not show another labeler's label in its place.
CARDIZEM
No label from the application holder was found in the openFDA label dataset for application NDA020027. This page does not show another labeler's label in its place.
CARDIZEM
No label from the application holder was found in the openFDA label dataset for application NDA020792. This page does not show another labeler's label in its place.
CARDIZEM CD
No label from the application holder was found in the openFDA label dataset for application NDA020062. This page does not show another labeler's label in its place.
CARDIZEM LA
No label from the application holder was found in the openFDA label dataset for application NDA021392. This page does not show another labeler's label in its place.
CARDIZEM SR
No label from the application holder was found in the openFDA label dataset for application NDA019471. This page does not show another labeler's label in its place.
DILACOR XR
No label from the application holder was found in the openFDA label dataset for application NDA020092. This page does not show another labeler's label in its place.
DILTIAZEM HYDROCHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA020939. This page does not show another labeler's label in its place.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA218038. This page does not show another labeler's label in its place.
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%
No label from the application holder was found in the openFDA label dataset for application NDA215252. This page does not show another labeler's label in its place.
TIAZAC
No label from the application holder was found in the openFDA label dataset for application NDA020401. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA018602 - Supplemental approval
NDA018602 - Supplemental approval
NDA018602 - Approval
NDA019471 - Approval
NDA020027 - Approval
NDA020062 - Approval
NDA020092 - Supplemental approval
NDA020062 - Supplemental approval
NDA020062 - Supplemental approval
NDA018602 - Supplemental approval
NDA020092 - Approval
NDA020401 - Approval
NDA020792 - Supplemental approval
NDA020401 - Approval
NDA020939 - Approval
NDA021392 - Supplemental approval
NDA021392 - Approval
NDA215252 - Approval
NDA218038
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the management of chronic stable angina as an indication: Stable angina
Applies to Recipient not specified People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm
The US label of CARDIZEM (diltiazem hydrochloride), in the Bausch Health US LLC version dated 2025-04-30 in openFDA, lists the medicine for the management of chronic stable angina and angina due to coronary artery spasm.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 11
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 6
Record details
- Record id
cardio:diltiazem- Content hash
a3ca390ad26d314abaedccd7a409bef33efd7cb4dd2743cff527c823d4c39537